Clinical Trial Update: Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV [Phase 3]

View source ↗

Summary

Phase 3 trial update on daclatasvir, asunaprevir plus ribavirin for hepatitis C genotype 1b without NS5A resistance-associated variants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED